Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA). Its presence may portend grave outcomes for those affected. The prevalence of ILD in RA ranges from 7.7% to 44% depending on the assessment tools used.
Treat-to-target is a common management strategy for rheumatoid arthritis that aims to employ the strategy most effective in terms of achievement of optimal therapeutic outcomes in RA.
Deloitte published its 2015 Healthcare Consumer Survey to examine online resource and technology use by patients. This is important, as the health care industry has expanded the development of online information resources, mobile applications, and personal health devices.
An analysis of 741,589 patients over age 45 years from southern Swedish registry examined patients who were followed (between 1998 and 2012) until a hip fracture, death or exit from the region occurred.
Healio reported the newly announced grant recipients from the Lupus Foundation of America.
Diffuse alveolar hemorrhage (DAH) is a rare but catastrophic complication of systemic lupus erythematosus. Presentations are usually acute and the potential for significant morbidity and mortality risk mandates early diagnosis and aggressive interventions.
The PROMISSE (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study has revealed several important lessons in lupus care.
Members of two professional medical societies griped about what they view as the Obama administration's inept attempts to regulate electronic health records (EHRs) and shared their visions for the ideal online platform at a second "town hall" meeting here Tuesday.
The range of categories and diagnostic possibilities is astronomical with the new ICD-10 and its 68,000 codes.
AMAGINE-2 and AMAGINE-3 are in two phase 3 studies that compare multiple doses of brodalumab (anti-IL-17) and ustekinumab (anti-12/23) in adults with moderate-to-severe psoriasis.
Biologic and new drug development seldom targets children and adolescents. This study evaluated the efficacy and safety of ustekinumab in adolescents age 12 to 17 years with moderate-to-severe psoriasis,
Mease and colleagues have published their results of a phase 3 trial of secukinumab (anti-IL-17A Mab) in 606 patients with psoriatic arthritis (PsA).
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
